Cargando…
Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy
Background: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the patients shows noticeable clinical response. Patients and Methods: Sixty-seven newly diagnosed NPC patients from 2005 to 2007 and 21 hea...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101529/ https://www.ncbi.nlm.nih.gov/pubmed/21614153 |
_version_ | 1782204281316704256 |
---|---|
author | Li, Jiang Chen, Qiu-yan Mo, Haoyuan Zhang, Yi-lan Huang, Zhou-feng Zeng, Yi-xin |
author_facet | Li, Jiang Chen, Qiu-yan Mo, Haoyuan Zhang, Yi-lan Huang, Zhou-feng Zeng, Yi-xin |
author_sort | Li, Jiang |
collection | PubMed |
description | Background: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the patients shows noticeable clinical response. Patients and Methods: Sixty-seven newly diagnosed NPC patients from 2005 to 2007 and 21 healthy donors were collected. Immunological parameters and immune function of PBMCs and EBV-CTL were analyzed by flow cytometer analysis (FACS) and (51)Cr releasing experiment; Molecular characteristics on NPC tumor cells were investigated by immunochemical staining and statistic analysis. Results: NPC patients can be classified into two groups based on the percentage of CD3(+) T cells in peripheral blood before accepted any treatment, (>52.6%, mean-2SE from healthy controls, NPC Group 1; <52.6%, NPC Group 2). The patients in Group 2 showed a significant decrease of CD3(+)CD8(+) T-cells, CD3(+)CD4(+) T-cells and CD3(+)CD45RO(+) memory T cells, and increase of CD3(-)CD16(+) NK cells compared to Group 1 patients and healthy controls (P<0.001). EBV-specific T cell responses, were weaker in this group of patients and their tumor cells expressed lower levels of the EBV encoded latent membrane protein (LMP)-1 and HLA class II protein compared with the patients of NPC Group 1 (P<0.05) . Conclusion: These findings demonstrate that NPC patients could be distinguished on the basis of their immune status which will affect the efficacy of EBV-CTL immunotherapy. |
format | Text |
id | pubmed-3101529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-31015292011-05-25 Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy Li, Jiang Chen, Qiu-yan Mo, Haoyuan Zhang, Yi-lan Huang, Zhou-feng Zeng, Yi-xin Int J Biol Sci Research Paper Background: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the patients shows noticeable clinical response. Patients and Methods: Sixty-seven newly diagnosed NPC patients from 2005 to 2007 and 21 healthy donors were collected. Immunological parameters and immune function of PBMCs and EBV-CTL were analyzed by flow cytometer analysis (FACS) and (51)Cr releasing experiment; Molecular characteristics on NPC tumor cells were investigated by immunochemical staining and statistic analysis. Results: NPC patients can be classified into two groups based on the percentage of CD3(+) T cells in peripheral blood before accepted any treatment, (>52.6%, mean-2SE from healthy controls, NPC Group 1; <52.6%, NPC Group 2). The patients in Group 2 showed a significant decrease of CD3(+)CD8(+) T-cells, CD3(+)CD4(+) T-cells and CD3(+)CD45RO(+) memory T cells, and increase of CD3(-)CD16(+) NK cells compared to Group 1 patients and healthy controls (P<0.001). EBV-specific T cell responses, were weaker in this group of patients and their tumor cells expressed lower levels of the EBV encoded latent membrane protein (LMP)-1 and HLA class II protein compared with the patients of NPC Group 1 (P<0.05) . Conclusion: These findings demonstrate that NPC patients could be distinguished on the basis of their immune status which will affect the efficacy of EBV-CTL immunotherapy. Ivyspring International Publisher 2011-05-18 /pmc/articles/PMC3101529/ /pubmed/21614153 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Research Paper Li, Jiang Chen, Qiu-yan Mo, Haoyuan Zhang, Yi-lan Huang, Zhou-feng Zeng, Yi-xin Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy |
title | Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy |
title_full | Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy |
title_fullStr | Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy |
title_full_unstemmed | Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy |
title_short | Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy |
title_sort | immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101529/ https://www.ncbi.nlm.nih.gov/pubmed/21614153 |
work_keys_str_mv | AT lijiang immunophenotypingatthetimeofdiagnosisdistinguishestwogroupsofnasopharyngealcarcinomapatientsimplicationsforadoptiveimmunotherapy AT chenqiuyan immunophenotypingatthetimeofdiagnosisdistinguishestwogroupsofnasopharyngealcarcinomapatientsimplicationsforadoptiveimmunotherapy AT mohaoyuan immunophenotypingatthetimeofdiagnosisdistinguishestwogroupsofnasopharyngealcarcinomapatientsimplicationsforadoptiveimmunotherapy AT zhangyilan immunophenotypingatthetimeofdiagnosisdistinguishestwogroupsofnasopharyngealcarcinomapatientsimplicationsforadoptiveimmunotherapy AT huangzhoufeng immunophenotypingatthetimeofdiagnosisdistinguishestwogroupsofnasopharyngealcarcinomapatientsimplicationsforadoptiveimmunotherapy AT zengyixin immunophenotypingatthetimeofdiagnosisdistinguishestwogroupsofnasopharyngealcarcinomapatientsimplicationsforadoptiveimmunotherapy |